150 related articles for article (PubMed ID: 24656526)
1. Uveal metastasis and myasthenia gravis in a patient with recurrent renal cell carcinoma treated with pazopanib.
Jebb A; Hadden P; Broom RJ
Clin Genitourin Cancer; 2014 Aug; 12(4):e143-6. PubMed ID: 24656526
[No Abstract] [Full Text] [Related]
2. [Another approach to targeted therapy of patients with metastatic renal carcinoma with progression in treatment with pazopanib:expert assessment by the Czech Cooperative Group for Metastatic Renal Carcinoma].
Büchler T; Finek J; Hájek J; Kocák I; Kubácková K; Lakomý R; Melichar B; Petruzelka L; Poprach A; Siffnerová M; Tomásek J; Vyzula R; Zemanová M;
Klin Onkol; 2013; 26(1):55-7. PubMed ID: 23607143
[No Abstract] [Full Text] [Related]
3. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
[TBL] [Abstract][Full Text] [Related]
4. Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity.
Schinzari G; Monterisi S; Signorelli D; Cona MS; Cassano A; Danza F; Barone C
Tumori; 2014; 100(6):e298-300. PubMed ID: 25688515
[TBL] [Abstract][Full Text] [Related]
5. [First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
Maráz A; Bodrogi I; Csejtei A; Dank M; Géczi L; Küronya Z; Mangel L; Petrányi A; Szûcs M; Bodoky G
Magy Onkol; 2013 Sep; 57(3):173-6. PubMed ID: 24107823
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapies: treating advanced kidney cancer-miles to go before we sleep.
Linehan WM; Srinivasan R
Nat Rev Clin Oncol; 2013 Nov; 10(11):614-5. PubMed ID: 24129349
[TBL] [Abstract][Full Text] [Related]
7. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
[TBL] [Abstract][Full Text] [Related]
8. Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma.
Bonate PL; Suttle AB
Cancer Chemother Pharmacol; 2013 Jul; 72(1):231-40. PubMed ID: 23715625
[TBL] [Abstract][Full Text] [Related]
9. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
Brotelle T; Bay JO
Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
[TBL] [Abstract][Full Text] [Related]
10. Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib.
Jacobs C; Kim DW; Straka C; Timmerman RD; Brugarolas J
J Clin Oncol; 2013 Mar; 31(7):e114-7. PubMed ID: 23319695
[No Abstract] [Full Text] [Related]
11. Pazopanib for the treatment of renal cancer.
Al-Marrawi MY; Rini B
Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
[TBL] [Abstract][Full Text] [Related]
12. Case report of a long-surviving man with metastatic renal cell carcinoma treated with pazopanib.
Ratta R; Santini D
Tumori; 2014; 100(2):e59-62. PubMed ID: 24852879
[TBL] [Abstract][Full Text] [Related]
13. Early and prolonged response to pazopanib in a patient with multiple metastases from renal cell carcinoma: a case report.
Biasco E; Antonuzzo A; Cianci C; Derosa L; Marconcini R; Farnesi A; Galli L
Tumori; 2014; 100(3):e83-6. PubMed ID: 25076257
[TBL] [Abstract][Full Text] [Related]
14. Pazopanib for the treatment of renal cell carcinoma.
Welsh SJ; Fife K
Future Oncol; 2015; 11(8):1169-79. PubMed ID: 25832874
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile.
Pal SK; Hossain DM; Zhang Q; Frankel PH; Jones JO; Carmichael C; Ruel C; Lau C; Kortylewski M
J Urol; 2015 Apr; 193(4):1114-21. PubMed ID: 25286010
[TBL] [Abstract][Full Text] [Related]
16. What next? Choosing second-line therapy in progressive renal cell carcinoma.
Bourlon MT; Kessler ER
Oncology (Williston Park); 2014 Sep; 28(9):794-6. PubMed ID: 25225803
[No Abstract] [Full Text] [Related]
17. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
Zivi A; Cerbone L; Recine F; Sternberg CN
Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
[TBL] [Abstract][Full Text] [Related]
19. Nasal tumoral lesion: challenge. Cutaneous metastasis of renal cell carcinoma.
Molgó M; Abarzúa Á; Giesen L; González S
Am J Dermatopathol; 2015 May; 37(5):405, 423-4. PubMed ID: 25893748
[No Abstract] [Full Text] [Related]
20. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.
Xu CF; Bing NX; Ball HA; Rajagopalan D; Sternberg CN; Hutson TE; de Souza P; Xue ZG; McCann L; King KS; Ragone LJ; Whittaker JC; Spraggs CF; Cardon LR; Mooser VE; Pandite LN
J Clin Oncol; 2011 Jun; 29(18):2557-64. PubMed ID: 21576632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
